# Chiesi Ventures

> Chiesi Ventures is a VC fund in Boston backing Biotechnology, Health Care and Therapeutics. See 6 investments, check sizes, portfolio. Updated Aug 2026.

- Type: VC Fund
- Location: Boston, United States
- Total investments: 6
- Last investment: Apr 2025
- Lead investor: 0%
- Last updated: Aug 2026
- LinkedIn: https://www.linkedin.com/company/chiesi-ventures
- Website: http://www.chiesiventures.com/

Chiesi Ventures is a venture capital firm that invests in early stage opportunities operating in the area of rare and orphan disorders. The company funds research and development opportunities for therapies of rare diseases and aims to improve the quality of diagnosis, disease management, care and therapy to all patients affected by rare diseases.It also aims to accelerate the expansion of the Chiesi network in the U.S. among universities, venture capital investors, rare disease patient organizations, and entrepreneurial companies developing treatments for rare diseases.On September 2, 2014, Chiesi Ventures and A. M. Pappas & Associates announced a strategic collaboration.Chiesi Ventures was founded on September 2, 2014, and is headquartered in Parma, Italy with presence in the United States. It is owned by Chiesi Group.

## Investment focus

### Industry

| Industry | Investments | Share |
| --- | --- | --- |
| Biotechnology | 3 | 50% |
| Health Care | 2 | 33% |
| Therapeutics | 2 | 33% |
| Pharmaceutical | 2 | 33% |
| Genetics | 1 | 17% |

7 industries tracked in total.

### Stage

| Stage | Investments | Share |
| --- | --- | --- |
| Series B | 3 | 50% |
| Series C | 1 | 17% |
| Venture - Series Unknown | 1 | 17% |

## Investments

| Company | Description | Amount | Stage | Date | Website |
| --- | --- | --- | --- | --- | --- |
| Glycomine | Glycomine is early-stage biotech working on replacement therapies for rare diseases. There are approximately 7,000 rare disorders worldwide. Each day more are being discovered. 95% of rare diseases have not one single FDA-approved treatment. Glycomine develops therapeutics for diseases that have no treatment options. | $115M | Series C | Apr 16, 2025 |  |
| Glycomine | Glycomine is early-stage biotech working on replacement therapies for rare diseases. There are approximately 7,000 rare disorders worldwide. Each day more are being discovered. 95% of rare diseases have not one single FDA-approved treatment. Glycomine develops therapeutics for diseases that have no treatment options. | $35M | Series B | Jun 23, 2021 |  |
| Aura Biosciences | Aura Biosciences is a biotechnology company that focuses on the development of drugs by using tumor-targeted pseudovirions. The company is applying nanotechnology to help fight cancer in the well-studied area of chemotherapeutics and the emerging field of RNAi. By safely eliminating cancer locally, they can treat early and transform the lives ofpeople with a wide range of cancers that are poorly managed today.The company's goal is to treat small ocular melanomas potentially long before the disease progresses and metastasizes to the liver, where it almost always is fatal. Aura Biosciences was founded in 2007 and is headquartered in Cambridge, Massachusetts. | $80M | Venture - Series Unknown | Mar 22, 2021 |  |
| Glycomine | Glycomine is early-stage biotech working on replacement therapies for rare diseases. There are approximately 7,000 rare disorders worldwide. Each day more are being discovered. 95% of rare diseases have not one single FDA-approved treatment. Glycomine develops therapeutics for diseases that have no treatment options. | $33M | Series B | Aug 07, 2019 |  |
| 4D Molecular Therapeutics | 4D Molecular Therapeutics is a biotechnology company.The Company designs, develops, and commercializes transformative gene therapeutic products for unmet medical conditions. | $90M | Series B | Sep 05, 2018 |  |
| Kezar Life Sciences | Kezar Life Sciences company focused on the discovery and development of drugs targeting protein homeostasis for autoimmune disorders. In parallel with this work, Christopher and Kezar co-founder Jack Taunton, Ph.D. collaborated on several research projects involving protein secretion. This collaboration inspired a belief in the strong synergiesbetween protein degradation and protein secretion, two fertile areas for drug discovery with platform potential. | $50M | Series B | Jul 25, 2017 |  |

6 of 6 investments shown.

## Co-investors
- [Novo Holdings](https://shizune.co/investors/profile/novo-a-s) — VC Fund, 3 deals together
- [Sanderling Ventures](https://shizune.co/investors/profile/sanderling-ventures) — VC Fund, 3 deals together
- [Abingworth](https://shizune.co/investors/profile/abingworth-management) — VC Fund, 2 deals together
- [Advent Life Sciences](https://shizune.co/investors/profile/advent-life) — VC Fund, 2 deals together
- [Asahi Kasei](https://shizune.co/investors/profile/asahi-kasei) — VC Fund, 2 deals together
- [Mission BioCapital](https://shizune.co/investors/profile/bioinnovation-capital) — VC Fund, 2 deals together

## Similar investors

### Similar stage
- [Alumni Ventures](https://shizune.co/investors/profile/alumni-ventures-group) — VC Fund
- [General Catalyst](https://shizune.co/investors/profile/general-catalyst-partners) — VC Fund
- [FJ Labs](https://shizune.co/investors/profile/fj-labs) — VC Fund

## FAQ

### What does Chiesi Ventures invest in?

Chiesi Ventures invests primarily in Biotechnology, Health Care and Therapeutics startups, most often at Series B and Series C stage. Most of the 6 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.

### When did Chiesi Ventures last invest?

The most recent investment recorded for Chiesi Ventures closed in Apr 2025. Shizune tracks 6 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.

### Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

# About Shizune
Shizune.co is an investor database. Core features:
- 48,091 startup investors (angels, VCs, accelerators, and others)
- Email, phone, LinkedIn (for intros), socials, and other contact data
- Updated daily from public funding news
- CSV and Excel export

The User can access the full database FOR FREE after signing up: shizune.co